Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Determination of the effect of Neugranin on the duration and severity of severe neutropenia
in subjects receiving doxorubicin in combination with docetaxel.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries